Compare CCI & RMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCI | RMD |
|---|---|---|
| Founded | 1994 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.6B | 36.4B |
| IPO Year | 1998 | 1995 |
| Metric | CCI | RMD |
|---|---|---|
| Price | $87.81 | $244.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $116.27 | ★ $289.09 |
| AVG Volume (30 Days) | ★ 2.8M | 939.4K |
| Earning Date | 10-22-2025 | 01-29-2026 |
| Dividend Yield | ★ 4.84% | 0.98% |
| EPS Growth | N/A | ★ 29.59 |
| EPS | N/A | ★ 9.77 |
| Revenue | ★ $6,420,000,000.00 | $5,257,400,000.00 |
| Revenue This Year | N/A | $9.85 |
| Revenue Next Year | $1.89 | $7.36 |
| P/E Ratio | ★ N/A | $25.02 |
| Revenue Growth | ★ 28.02 | 9.36 |
| 52 Week Low | $84.20 | $199.92 |
| 52 Week High | $115.76 | $293.81 |
| Indicator | CCI | RMD |
|---|---|---|
| Relative Strength Index (RSI) | 43.48 | 41.85 |
| Support Level | $84.21 | $241.66 |
| Resistance Level | $92.75 | $247.45 |
| Average True Range (ATR) | 1.94 | 5.02 |
| MACD | -0.13 | -0.37 |
| Stochastic Oscillator | 42.74 | 14.57 |
Crown Castle owns or manages roughly 40,000 wireless towers in the United States. It leases space on its towers to wireless service providers, which install equipment to support their wireless networks. The company has a very concentrated customer base, with about 75% of its revenue from the Big Three US mobile carriers: Verizon, T-Mobile, and AT&T. Crown has plans to divest its fiber business, which is expected to be finalized in 2026. After that, it will be a stand-alone tower operator. Crown Castle operates as a real estate investment trust.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.